Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Hold” by Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned an average rating of “Hold” from the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $79.3077.

A number of analysts recently commented on the company. Leerink Partners boosted their target price on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. Stephens lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Evercore ISI lowered shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th.

Hologic Stock Performance

NASDAQ:HOLX opened at $75.05 on Monday. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. Hologic has a twelve month low of $51.90 and a twelve month high of $75.34. The company has a fifty day moving average of $74.80 and a 200-day moving average of $70.60. The firm has a market capitalization of $16.75 billion, a P/E ratio of 30.26, a P/E/G ratio of 2.13 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period last year, the company posted $1.01 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Hologic will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Harbor Capital Advisors Inc. bought a new position in Hologic during the 4th quarter valued at $27,000. Winnow Wealth LLC purchased a new stake in shares of Hologic in the third quarter valued at about $26,000. Root Financial Partners LLC bought a new position in shares of Hologic during the third quarter valued at about $27,000. Chung Wu Investment Group LLC purchased a new position in Hologic during the second quarter worth about $26,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.